Developments in microarray technologies.

Abstract:

:The focus of high-throughput drug discovery has progressed through the genome and the transcriptome and is now moving towards more difficult problems in assessing the proteome, glycome and metabolome. Microarrays are currently the major tool in the assessment of gene expression via cDNA or RNA analysis; however, they are also used to screen libraries of proteins and small molecules. Microarrays have helped to extract more information from smaller sample volumes and enabled the incorporation of low-cost high-throughput assays in the drug discovery process. The technology continues to develop and is being rapidly transferred into more challenging areas, with the potential to further aid and enhance the drug discovery process through the development of, for example, proteomic, glycomic and tissue arrays.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Howbrook DN,van der Valk AM,O'Shaughnessy MC,Sarker DK,Baker SC,Lloyd AW

doi

10.1016/s1359-6446(03)02773-9

subject

Has Abstract

pub_date

2003-07-15 00:00:00

pages

642-51

issue

14

eissn

1359-6446

issn

1878-5832

pii

S1359644603027739

journal_volume

8

pub_type

杂志文章,评审
  • Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling.

    abstract::In recent years, advances in tissue engineering and microfabrication technologies have enabled rapid growth in the areas of in vitro organoid development as well as organoid-on-a-chip platforms. These 3D model systems often are able to mimic human physiology more accurately than traditional 2D cultures and animal mode...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.07.003

    authors: Skardal A,Shupe T,Atala A

    更新日期:2016-09-01 00:00:00

  • The multiple therapeutic applications of miRNAs for bone regenerative medicine.

    abstract::With the aging of the general population, there is an increasing need for bone defect repair, prompting the development of reliable alternatives to autologous bone grafting, without the usually associated major drawbacks (i.e., limited volume and severe postoperative pain). Given the crucial role that miRNAs appear to...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.007

    authors: Scimeca JC,Verron E

    更新日期:2017-07-01 00:00:00

  • Pharmacokinetics and the drug-target residence time concept.

    abstract::The concept of drug-target residence time has been in focus in recent drug discovery literature. However, few studies consider the combined effect of pharmacokinetics (PK) and binding kinetics (BK) on the duration of effect of a drug. Using a simple model that takes both PK and BK into account, we found that prolongat...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.02.010

    authors: Dahl G,Akerud T

    更新日期:2013-08-01 00:00:00

  • Docking optimization, variance and promiscuity for large-scale drug-like chemical space using high performance computing architectures.

    abstract::There is a continuing need to hasten and improve protein-ligand docking to facilitate the next generation of drug discovery. As the drug-like chemical space reaches into the billions of molecules, increasingly powerful computer systems are required to probe, as well as tackle, the software engineering challenges neede...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.06.023

    authors: Trager RE,Giblock P,Soltani S,Upadhyay AA,Rekapalli B,Peterson YK

    更新日期:2016-10-01 00:00:00

  • Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors.

    abstract::Telomerase is a ribonucleic reverse transcriptase enzyme that uses an integral RNA component as a template to add tandem telomeric DNA repeats, TTAGGG, at the 3' end of the chromosomes. 85-90% of human tumors and their derived cell lines predominantly express high levels of telomerase, therefore contributing to cancer...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.05.015

    authors: Saraswati AP,Relitti N,Brindisi M,Gemma S,Zisterer D,Butini S,Campiani G

    更新日期:2019-07-01 00:00:00

  • The power of combining phenotypic and target-focused drug discovery.

    abstract::A fierce dispute has arisen between the supporters of phenotypic and target-focused screening regarding which path grants the higher probability of successful drug development. A chance to reconcile these two approaches lies in successful target deconvolution (TD) after phenotypic screens. But, despite the panoply of ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.10.009

    authors: Heilker R,Lessel U,Bischoff D

    更新日期:2019-02-01 00:00:00

  • Current status and future prospects of toxicogenomics in drug discovery.

    abstract::In drug discovery and development (DDD), the efficacy, safety and cost of new chemical entities are the main concerns of the pharmaceutical industry. Continuously updated and stricter recommendations imposed by regulatory authorities result in greater challenges being faced by the industry. Reliable high-throughput te...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.11.001

    authors: Khan SR,Baghdasarian A,Fahlman RP,Michail K,Siraki AG

    更新日期:2014-05-01 00:00:00

  • The MEK5/ERK5 signalling pathway in cancer: a promising novel therapeutic target.

    abstract::Conventional mitogen-activated protein kinase (MAPK) family members are among the most sought-after oncogenic effectors for the development of novel human cancer treatment strategies. MEK5/ERK5 has been the less-studied MAPK subfamily, despite its increasingly demonstrated relevance in the growth, survival, and differ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.06.010

    authors: Simões AE,Rodrigues CM,Borralho PM

    更新日期:2016-10-01 00:00:00

  • Molecular diversity and its analysis.

    abstract::We have recently developed a novel strategy for the rational design of compounds. This 'in silico screening' approach is based on the design and screening of virtual combinatorial libraries. Screening is performed using defined rules derived from a comprehensive description of active and inactive molecules in a releva...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(99)01334-3

    authors: Gorse D,Rees A,Kaczorek M,Lahana R

    更新日期:1999-06-01 00:00:00

  • Tuberculosis: from molecular pathogenesis to effective drug carrier design.

    abstract::In the past two decades, tuberculosis has gone from being a forgotten disease to a modern and recrudescent pathology. Tuberculosis is a curable infection and most of the negative therapeutic outcomes are related to poor patient compliance, which could be solved by new drug delivery approaches. By using such approaches...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.03.012

    authors: Dube D,Agrawal GP,Vyas SP

    更新日期:2012-07-01 00:00:00

  • Compound high-quality criteria: a new vision to guide the development of drugs, current situation.

    abstract::For several decades, the pharmaceutical industry has suffered due to major issues such as reductions of the number of FDA approved drugs and biologics. Several analyses have been highlighted that the 'druglikeness' is one of the strategies to improve succeed rates of screening such as, for instance, high-throughput sc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.01.005

    authors: Mignani S,Huber S,Tomás H,Rodrigues J,Majoral JP

    更新日期:2016-04-01 00:00:00

  • Advances in the computational development of DNA methyltransferase inhibitors.

    abstract::DNA methylation is an epigenetic change that results in the addition of a methyl group at the carbon-5 position of cytosine residues. The process is mediated by DNA methyltransferases (DNMTs), a family of enzymes for which inhibition is a promising strategy for the treatment of cancer and other diseases. Here, we revi...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.02.003

    authors: Medina-Franco JL,Caulfield T

    更新日期:2011-05-01 00:00:00

  • Homologous recombination in human iPS and ES cells for use in gene correction therapy.

    abstract::The emergence of induced pluripotent stem (iPS) cell technology has shifted gene correction therapy toward reality. Crucial issues are ensuring the safety of using iPS cell technology in patients and discovering how best to transfer genetically manipulated iPS cells back into patients. One key issue that has hindered ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.01.006

    authors: Nakayama M

    更新日期:2010-03-01 00:00:00

  • Cancer therapy via modulation of micro RNA levels: a promising future.

    abstract::Micro RNAs (miRNAs) are a class of naturally occurring ∼ 22 nt long non-coding small RNA molecules that regulate the expression of a wide range of genes involved in development, growth, proliferation and apoptosis. miRNAs are evolutionarily conserved from plants to animals, and they regulate and fine-tune a diverse ar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.07.003

    authors: Kota SK,Balasubramanian S

    更新日期:2010-09-01 00:00:00

  • Computational chemistry-driven decision making in lead generation.

    abstract::Novel starting points for drug discovery projects are generally found either by screening large collections of compounds or smaller more-focused libraries. Ideally, hundreds or even thousands of actives are initially found, and these need to be reduced to a handful of promising lead series. In several sequential steps...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03703-7

    authors: Schnecke V,Boström J

    更新日期:2006-01-01 00:00:00

  • DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns.

    abstract::DNA-nanorobot-guided thrombin-inducing tumor infarction (DNA NanorobotTh-ITI) is emerging as a powerful therapeutic strategy for treatment of solid cancers. The technology represents a major advance in the application of DNA nanotechnology for anticancer therapy. More importantly, the technology is being translated fr...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2020.03.005

    authors: Zheng K,Kros JM,Li J,Zheng PP

    更新日期:2020-06-01 00:00:00

  • Understanding the checkpoint blockade in lung cancer immunotherapy.

    abstract::Immunotherapies have changed the treatment strategy of some types of tumor including melanoma and, more recently, non-small-cell lung cancer (NSCLC). Immune checkpoints are crucial for the maintenance of self-tolerance and it is known that some tumors use checkpoint systems to evade antitumor immune response. The trea...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.05.016

    authors: Dal Bello MG,Alama A,Coco S,Vanni I,Grossi F

    更新日期:2017-08-01 00:00:00

  • Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation.

    abstract::In recent years there has been a dramatic increase in the number of freely accessible online databases serving the chemistry community. The internet provides chemistry data that can be used for data-mining, for computer models, and integration into systems to aid drug discovery. There is however a responsibility to en...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.02.013

    authors: Williams AJ,Ekins S,Tkachenko V

    更新日期:2012-07-01 00:00:00

  • Mimicking the 3D biology of osteochondral tissue with microfluidic-based solutions: breakthroughs towards boosting drug testing and discovery.

    abstract::The development of tissue-engineering (TE) solutions for osteochondral (OC) regeneration has been slowed by technical hurdles related to the recapitulation of their complex and hierarchical architecture. OC defects refer to damage of both the articular cartilage and the underlying subchondral bone. To repair an OC tis...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.01.008

    authors: Carvalho MR,Reis RL,Oliveira JM

    更新日期:2018-03-01 00:00:00

  • Bioscience industry in metro Atlanta.

    abstract::One of the world's fastest growing cities, Atlanta is the business center of the Southeast U.S. and is rapidly becoming a leader for biotechnology innovation. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/S1359-6446(05)03374-X

    authors: Allen CR

    更新日期:2005-02-15 00:00:00

  • Targeting mutant huntingtin for the development of disease-modifying therapy.

    abstract::Huntington's disease (HD) is a progressive and fatal neurodegenerative disease, and the most common inherited CAG repeat disorder. A polyglutamine expansion in the N-terminus of the huntingtin protein (HTT) leads to protein misfolding and downstream pathogenic processes culminating in widespread functional impairment ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.06.017

    authors: Appl T,Kaltenbach L,Lo DC,Terstappen GC

    更新日期:2012-11-01 00:00:00

  • Histone acetyl transferases as emerging drug targets.

    abstract::Post-translational modifications, such as acetylation or phosphorylation, play a crucial role in the regulation of gene transcription in eukaryotes. Different subtypes of histone acetyl transferases (HATs) catalyze the acetylation of histones on specific lysine residues. A potential role of HATs in the pathology of ca...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.06.008

    authors: Dekker FJ,Haisma HJ

    更新日期:2009-10-01 00:00:00

  • 'The 39 steps' in gene expression profiling: critical issues and proposed best practices for microarray experiments.

    abstract::Gene expression microarrays have been used widely to address increasingly complex biological questions and to produce an unprecedented amount of data, but have yet to realize their full potential. The interpretation of microarray data remains a major challenge because of the complexity of the underlying biological net...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03565-8

    authors: Imbeaud S,Auffray C

    更新日期:2005-09-01 00:00:00

  • Molecule-pharmacophore superpositioning and pattern matching in computational drug design.

    abstract::Three-dimensional (3D) pharmacophore modeling is a technique for describing the interaction of a small molecule ligand with a macromolecular target. Since chemical features in a pharmacophore model are well known and highly transparent for medicinal chemists, these models are intuitively understandable and have been i...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.09.007

    authors: Wolber G,Seidel T,Bendix F,Langer T

    更新日期:2008-01-01 00:00:00

  • Discovery informatics: its evolving role in drug discovery.

    abstract::Drug discovery and development is a highly complex process requiring the generation of very large amounts of data and information. Currently this is a largely unmet informatics challenge. The current approaches to building information and knowledge from large amounts of data has been addressed in cases where the types...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(02)02433-9

    authors: Claus BL,Underwood DJ

    更新日期:2002-09-15 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01566-x

    authors: Edwards P

    更新日期:2000-10-01 00:00:00

  • Dopaminergic agents for the treatment of cocaine abuse.

    abstract::Cocaine is a major drug of abuse whose devastating effects have captured the attention of health officials and policy makers. Based upon the alarming health and crime-related costs associated with the use of this powerful reinforcing drug, immediate therapies are needed for the treatment of cocaine addiction. In this ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(99)01332-x

    authors: Smith MP,Hoepping A,Johnson KM,Trzcinska M,Kozikowski AP

    更新日期:1999-07-01 00:00:00

  • An analysis of FDA-approved drugs for cardiovascular diseases.

    abstract::Following the introduction of antibiotic therapy and widespread inoculations, cardiovascular diseases have leapt ahead of infectious diseases in terms of prevalence in much of the developed and developing world. Herein, we assess FDA-approved drugs for the treatment of cardiovascular diseases. The drug development ent...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2014.09.001

    authors: Kinch MS,Surovtseva Y,Hoyer D

    更新日期:2016-01-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01877-3

    authors: Barlocco D,Langston S,Tranter D

    更新日期:2001-08-01 00:00:00

  • Deformylase as a novel antibacterial target.

    abstract::Bacterial genomics has revealed a plethora of previously unknown targets of potential use in the discovery of novel antibacterial drugs. However, so far little has emerged from this approach. Peptide deformylase is an interesting target that was discovered more than 30 years ago, but was not exploited until recently. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01925-0

    authors: Yuan Z,Trias J,White RJ

    更新日期:2001-09-15 00:00:00